Meniscus Implant

April 28, 2009 11:08 AM Eastern Daylight Time
ReGen Biologics Employs Industry Veteran To Lead Training
HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBO), which manufactures and distributes a meniscus implant for use in arthroscopic surgery to address the most common form of knee injury, has hired an executive with nearly two decades of orthopaedics experience to lead the company’s surgeon education and training program.

Cameron McCaa, as Director of Education and Training, will lead efforts already underway to train U.S. surgeons on the Menaflex™ collagen meniscus implant. The device is inserted during knee meniscus surgery to facilitate tissue growth, thereby reinforcing and repairing the damaged meniscus.

“Recruiting a seasoned industry executive to oversee the surgeon training programs demonstrates ReGen’s commitment to ensuring that surgeons, who already have shown a high interest in the Menaflex device, are fully informed about the role it plays in meniscus preservation efforts,” said ReGen Chairman and CEO Gerald E. Bisbee Jr., Ph.D.

ReGen has undertaken training throughout the United States to provide surgeons with practical guidance on insertion and use of the Menaflex device.

Mr. McCaa noted, “This device, which was cleared last year by the U.S. Food and Drug Administration, has been in use in Europe for a number of years. Part of my mission will be to ensure U.S. surgeons learn of patient results in Europe, as well as in the clinical studies here in the United States.”

In addition to overseeing the surgeon training programs, Mr. McCaa will lead training efforts for sales staff and other employees.

“Cam’s extensive business background in orthopedic sales and marketing, plus his history with meniscus preservation while working with Cryolife, offer a great combination of practical and academic insight,” commented Jeff Chandler, ReGen’s Senior Vice President of Sales and Marketing.

Mr. McCaa previously worked for End Range of Motion Improvement, Inc., Infinity Orthopaedics, LLC, and Cryolife, Inc. He received a bachelor of science in mechanical engineering from Christian Brothers University and a Master of Science degree in mechanical and biomedical engineering from the University of Texas.

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen’s Menaflex™ collagen meniscus implant employs proprietary biological collagen scaffold technology to facilitate tissue growth, thereby reinforcing and repairing the damaged meniscus of the knee. The Menaflex device has been cleared for sale in Europe and other countries, and is marketed through ReGen’s European subsidiary, ReGen Biologics AG. The FDA cleared the Menaflex device for marketing in the United States in December 2008. Visit www.regenbio.com and www.menaflex.com for more information.

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of ReGen management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2008 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.


Contacts
ReGen Biologics, Inc.
Donna Lucchesi, 480-634-6923
donna@LBCsuccess.com